公开(公告)号：US11628209B2

公开(公告)日：2023-04-18

申请号：US16229841

申请日：2018-12-21

Applicant: BIONTECH AG ,  TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gemeinnützige GmbH

Inventor： Ugur Sahin ,  Claudia Paret ,  Kirsten Vormbrock ,  Christian Bender ,  Petra Simon ,  Christoph Hartmann ,  Stefanie Hubich ,  Thomas Bukur ,  Thorsten Litzenberger

IPC: G01N31/00 ,  G01N33/53 ,  A61K39/00 ,  C07K14/47 ,  C12Q1/6886 ,  G01N33/574

Abstract: The present invention relates to the treatment of cancer, in particular breast cancer, particularly triple-negative breast cancer. More particularly, the invention concerns methods and means for cancer treatment involving a specific set of tumor antigens.

公开(公告)号：US20190055311A1

公开(公告)日：2019-02-21

申请号：US16117197

申请日：2018-08-30

Applicant: Biontech AG ,  Ganymed Pharmaceuticals AG ,  TRON-Translationale Onkologie An der Universitatsm Edizin der Johannes Gutenberg-Universitat Mainz

Inventor： Ugur Sahin ,  Ozlem Türeci ,  Christiane Stadler ,  Julia Holland ,  Hayat Bähr-Mahmud ,  Tim Beissert ,  Laura Plum ,  Fabrice Le Gall ,  Arne Jendretzki ,  Markus Fiedler

IPC: C07K16/28 ,  C07K16/30 ,  A61K39/00

Abstract: The present invention provides binding agents that contain n binding domain that is specific for CD3 allowing binding to T cells and a binding domain that is specific for a tumor-associated claudin molecule and methods of using these binding agents or nucleic acids encoding therefor for treating cancer.

公开(公告)号：US09950065B2

公开(公告)日：2018-04-24

申请号：US15023052

申请日：2013-09-26

Applicant: BIONTECH AG ,  TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gemeinnützige GmbH ,  UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ

Inventor： Ugur Sahin ,  Heinrich Haas ,  Sebastian Kreiter ,  Yves Hüsemann ,  Mustafa Diken ,  Kerstin Reuter ,  Hossam Hefresha

IPC: A61K39/39 ,  A61K39/00 ,  A61K9/127 ,  A61K9/50 ,  A61K31/675 ,  C12N15/88

CPC classification number: A61K39/39 ,  A61K9/1271 ,  A61K9/1277 ,  A61K9/5073 ,  A61K31/675 ,  A61K39/0011 ,  A61K2039/55505 ,  A61K2039/55511 ,  A61K2039/55516 ,  A61K2039/55555 ,  A61K2039/55561 ,  A61K2039/572 ,  C12N15/88 ,  C12N2810/10

Abstract: The present invention relates to RNA decorated particles such as RNA decorated lipid particles, preferably to RNA decorated liposomes. Further, the present invention relates to a pharmaceutical composition comprising RNA decorated particles such as RNA decorated lipid particles, preferably RNA decorated liposomes. Said pharmaceutical composition is useful for inducing an immune response. It is also useful in a prophylactic and/or therapeutic treatment of a disease involving an antigen. Furthermore, the present invention relates to a method for producing the RNA decorated particles such as RNA decorated lipid particles, preferably RNA decorated liposomes.

公开(公告)号：US09910043B2

公开(公告)日：2018-03-06

申请号：US15046700

申请日：2016-02-18

Applicant: BioNTech AG

Inventor： Özlem Türeci ,  Ugur Sahin ,  Gerd Helftenbein ,  Volker Schlüter

IPC: G01N33/574 ,  C07K14/47 ,  C07K14/705 ,  C07K16/30 ,  C12Q1/68 ,  A61K39/00

CPC classification number: G01N33/57492 ,  A61K2039/505 ,  C07K14/4748 ,  C07K14/705 ,  C07K16/30 ,  C07K2317/34 ,  C12Q1/6886 ,  C12Q2600/112 ,  C12Q2600/158 ,  G01N2800/56

Abstract: The present invention provides agents with tumor-inhibiting activity, and which are selective for cells expressing or abnormally expressing a tumor-associated antigen. Said tumor-associated antigen has a nucleotide sequence selected from the group consisting of: (a) a nucleotide sequence selected from the specific sequences set forth herein, or a 6-50 contiguous nucleotide residue portion thereof; (b) a nucleotide sequence of a nucleic acid which hybridizes with a nucleic acid having the nucleotide sequence of (a) under stringent conditions; (c) a nucleotide sequence which is degenerate with respect to the nucleotide sequence of (a) or (b); and (d) a nucleotide sequence which is complementary to the nucleotide sequence of (a), (b) or (c). Pharmaceutical compositions and kits comprising the agents are also provided, as well as methods treating, diagnosing or monitoring a disease characterized by expression or abnormal expression of the tumor-associated antigen.

公开(公告)号：US09637794B2

公开(公告)日：2017-05-02

申请号：US13796094

申请日：2013-03-12

Applicant: BioNTech AG

Inventor： Ugur Sahin ,  Özlem Türeci ,  Michael Koslowski

IPC: C12Q1/68 ,  C07K14/47 ,  C07K16/30 ,  A61K39/395 ,  A61K38/00 ,  A61K39/00 ,  A61K48/00 ,  G01N33/574

CPC classification number: C07K16/30 ,  A61K38/00 ,  A61K39/00 ,  A61K39/39558 ,  A61K48/00 ,  C07K14/4748 ,  C07K16/3015 ,  C07K16/3023 ,  C07K16/3053 ,  C07K16/3069 ,  C07K2317/34 ,  C07K2317/76 ,  C12Q1/6886 ,  C12Q2600/112 ,  C12Q2600/158 ,  G01N33/574

Abstract: The invention relates to the identification of genetic products that are expressed in association with a tumor and the nucleic acid coding therefor. The invention relates to the therapy and diagnosis of diseases in which the genetic products that are expressed in association with a tumor are expressed in an aberrant manner. The invention also relates to proteins, polypeptides, and peptides which are expressed in association with a tumor and the nucleic acids coding therefor.

公开(公告)号：US20170072035A1

公开(公告)日：2017-03-16

申请号：US15341528

申请日：2016-11-02

Applicant: BioNTech AG

Inventor： Thorsten Klamp ,  Ugur Sahin ,  Ozlem Tureci ,  Michael Koslowski ,  Thomas Hiller ,  Jens Schumacher

IPC: A61K39/00 ,  C07K14/47 ,  C12N7/00 ,  C07K14/005

Abstract: The present invention relates to tumor immunotherapy, in particular to tumor vaccination, using chimeric proteins comprising all or a portion of a hepatitis B virus core antigen protein and an amino acid sequence comprising an epitope derived from the extracellular portion of a tumor-associated antigen. In particular, the present invention provides virus-like particles comprising said chimeric proteins, which are useful for eliciting a humoral immune response in a subject against the tumor-associated antigen, in particular against cells carrying said tumor-associated antigen on their surface, wherein the tumor-associated antigen is a self-protein in said subject.

Abstract translation: 本发明涉及使用包含全部或部分乙型肝炎病毒核心抗原蛋白的嵌合蛋白和包含衍生自肿瘤相关抗原的细胞外部分的表位的氨基酸序列的肿瘤免疫治疗，特别是肿瘤免疫治疗。 特别地，本发明提供了包含所述嵌合蛋白的病毒样颗粒，其可用于在受试者内针对肿瘤相关抗原，特别是针对在其表面上携带所述肿瘤相关抗原的细胞引起体液免疫应答，其中 肿瘤相关抗原是所述受试者中的自身蛋白质。

公开(公告)号：US20170007776A1

公开(公告)日：2017-01-12

申请号：US15115384

申请日：2014-02-05

Applicant: BIONTECH AG ,  TRON - Translationale Onkologie an der Universitätsmedizin der Johannes Gutenbert-Univer

Inventor： Ugur Sahin

IPC: A61M5/32 ,  A61M5/315

CPC classification number: A61M5/3291 ,  A61M5/315 ,  A61M5/3286

Abstract: The present invention provides a cannula (300) with a distal end (311) and a proximal end (312), comprising a sidewall (301) defining a lumen (302) for receiving a fluid (800) from a feeding device (400, 500), wherein the sidewall (301) comprises a plurality of openings (303) for supplying the fluid (800) into a target tissue (700) of a patient. Each opening (304) is in fluid communication with the lumen (302) of the cannula (300). Furthermore, an injection or infusion device (100, 200) is provided, comprising said cannula (300) and a feeding device (400, 500) for supplying the fluid (800) to the cannula (300), wherein the cannula (300) is attached or is configured to be attachable to the feeding device (400, 500). Corresponding methods are also provided, using said cannula and/or said injection or infusion device (100, 200).

Abstract translation: 本发明提供一种具有远端（311）和近端（312）的插管（300），其包括限定用于从进给装置（400）接收流体（800）的内腔（302）的侧壁（301） 500），其中所述侧壁（301）包括用于将流体（800）供应到患者的靶组织（700）中的多个开口（303）。 每个开口（304）与插管（300）的内腔（302）流体连通。 此外，提供注射或输注装置（100,200），其包括所述插管（300）和用于将流体（800）供应到插管（300）的进给装置（400,500），其中所述插管（300） 被附接或被构造成可附接到所述进给装置（400,500）。 还提供了相应的方法，使用所述套管和/或所述注射或输注装置（100,200）。

公开(公告)号：US09533043B2

公开(公告)日：2017-01-03

申请号：US14036969

申请日：2013-09-25

Applicant: BioNTech AG

Inventor： Özlem Türeci ,  Ugur Sahin ,  Sandra Schneider ,  Gerd Helftenbein ,  Volker Schlüter ,  Dirk Usener ,  Philippe Thiel ,  Michael Koslowski

IPC: A61K39/395 ,  A61K51/10 ,  A61K47/42 ,  C07K16/30 ,  C12Q1/68 ,  C07K14/47 ,  A61K45/06 ,  C07K16/28 ,  A61P35/00 ,  G01N33/53

CPC classification number: A61K39/39558 ,  A61K39/395 ,  A61K45/06 ,  C07K14/4748 ,  C07K16/28 ,  C07K16/30 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/156 ,  G01N33/53

Abstract: An isolated truncated desmoglein 4 (DSG4) polypeptide splice variant of the invention is characterized by an amino acid sequence that lacks a region encoded before exon 9 or beyond exon 10 of the DSG4 gene having the polynucleotide sequence of SEQ ID NO: 75. Also disclosed is a method of diagnosing a cancer, or monitoring the course thereof, in a patient. The method comprises detecting in a tissue sample of a patient the expression of a tumor-associated antigen comprising the extracellular domain of a DSG4 polypeptide encoded by a DSG4 gene having the polynucleotide sequence of SEQ ID NO: 75, or a truncated DSG4 polypeptide splice variant characterized by an amino acid sequence that lacks a region encoded before exon 9 or beyond exon 10 of the DSG4 gene.

Abstract translation: 本发明的分离的截短的脱骨髓蛋白4（DSG4）多肽剪接变体的特征在于缺乏在具有SEQ ID NO：75的多核苷酸序列的DSG4基因的外显子9或超出外显子10之前编码的区域的氨基酸序列。还公开了 是在患者中诊断癌症或监测其过程的方法。 该方法包括在患者的组织样品中检测包含由具有SEQ ID NO：75的多核苷酸序列的DSG4基因或截短的DSG4多肽剪接变体编码的DSG4多肽的细胞外结构域的肿瘤相关抗原的表达 其特征在于缺乏在DSG4基因的外显子9或超出外显子10之前编码的区域的氨基酸序列。

公开(公告)号：US20160125129A1

公开(公告)日：2016-05-05

申请号：US14787110

申请日：2014-05-07

Applicant: BIONTECH AG ,  TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄ- TSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAIN

Inventor： Ugur Sahin ,  Arbel David Tadmor ,  John Christopher Castle ,  Sebastian Boegel ,  Martin Löwer

IPC: G06F19/18 ,  A61K39/00 ,  C12Q1/68

CPC classification number: G16B20/00 ,  A61K39/0011 ,  C12Q1/6886 ,  C12Q2600/156

Abstract: The present invention relates to methods for predicting T cell epitopes. In particular, the present invention relates to methods for predicting whether modifications in peptides or polypeptides such as tumor-associated neoantigens are immunogenic or not. The methods of the invention are useful, in particular, for the provision of vaccines which are specific for a patient's tumor and, thus, in the context of personalized cancer vaccines.

Abstract translation: 本发明涉及预测T细胞表位的方法。 特别地，本发明涉及用于预测肽或多肽如肿瘤相关新抗原的修饰是否是免疫原性的方法。 本发明的方法特别适用于提供特异于患者肿瘤的疫苗，因此在个体化的癌症疫苗的背景下。

公开(公告)号：US09061007B2

公开(公告)日：2015-06-23

申请号：US13826030

申请日：2013-03-14

Applicant: BioNTech AG ,  Johannes Gutenberg-Universität Mainz

Inventor： Ugur Sahin ,  Ozlem Tureci ,  Michael Koslowski

IPC: A61K31/21 ,  A61K39/395 ,  C12Q1/68 ,  G01N33/574 ,  A61K31/7088 ,  C12N15/82 ,  A61K47/48

CPC classification number: C12Q1/6886 ,  A61K31/7088 ,  A61K39/39558 ,  A61K47/6807 ,  C07K16/28 ,  C07K16/2866 ,  C07K16/40 ,  C07K2317/76 ,  C12N15/1138 ,  C12N15/8218 ,  C12N2310/11 ,  C12N2310/14 ,  C12Q2600/118 ,  C12Q2600/154 ,  C12Q2600/158 ,  G01N33/57484 ,  G01N33/57492 ,  G01N2333/715 ,  G01N2333/7158 ,  G01N2333/916

Abstract: The present invention relates to methods which make possible to assess and/or prognose a cancer disease, the metastatic behavior of a cancer disease and/or the occurrence of a relapse of cancer. In particular, the methods of the invention make possible to assess and/or prognose the occurrence of cancer metastasis, in particular distant metastasis. Preferably, the methods of the invention allow to discriminate malign from benign conditions.

Abstract translation: 本发明涉及有可能评估和/或预测癌症疾病，癌症疾病的转移行为和/或癌症复发的方法。 特别地，本发明的方法使得有可能评估和/或预测癌症转移的发生，特别是远处转移。 优选地，本发明的方法允许区分恶性与良性状况。